Geistlich Derma-Gide® reaches an important milestone
This GSA approval paves the way for physicians and staff of veterans' administration health facilities to use Geistlich Derma-Gide® for the treatment of wounds that are difficult to heal. The product is approved by the U.S. Food and Drug Administration (FDA) for a variety of indications, including diabetic foot ulcers, venous leg ulcers, surgical wounds and first and second-degree burns.
The two-layer product design of Geistlich Derma-Gide® mimics the structural organization of human skin, thus facilitating the ingrowth of cells. For this matrix, which is currently available on the US market, Geistlich uses two different, specific porcine source tissues. The Geistlich scientists transformed the source tissue into a high-tech designed matrix. This provides the precise properties required to support wound healing. Geistlich Derma-Gide® received further recognition by being named one of the ten "top innovations" in the American scientific journal "PodiatryToday" in 2020 (Volume 33 | Number 7 | July 2020). Geistlich thus repeatedly stands for pioneering progress and as a driver of regeneration.